ArticleEmerging infectious diseases2022
Burden of Tick-Borne Encephalitis, Sweden.
Article in Emerging infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Projecting tick-borne encephalitis risk in Sweden under climate change scenarios: a high-resolution spatio-temporal modeling approach.Environmental health : a global access science source · 2026Article
- Nationwide Analysis of In-Hospital Mortality in Patients with Encephalitis-Related Diagnoses in Ecuador.Diseases (Basel, Switzerland) · 2026Article
- Article
- Clinical Characteristics of Tick-Borne Encephalitis in Adult Patients: A 10-year Retrospective Study in Stockholm, Sweden.The Journal of infectious diseases · 2025Article
- Tick-borne encephalitis vaccine uptake, effectiveness, and impact in Sweden from 2018 to 2022.Scientific reports · 2025Article
- Neurotropic Tick-Borne Flavivirus in Alpine Chamois (Viruses · 2025Article
- The impact of serological testing implementation on tick-borne encephalitis detection in Poland.PloS one · 2025Article
- What makes patients tick? Vaccine preferences against tick-borne encephalitis in four European countries.BMC infectious diseases · 2024Article
- Transcriptional Response to Tick-Borne Flavivirus Infection in Neurons, Astrocytes and Microglia In Vivo and In Vitro.Viruses · 2024Article
- Clinical characteristics and factors affecting disease severity in hospitalized tick-borne encephalitis patients in Norway from 2018 to 2022.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Observational
- Severe Tick-Borne Encephalitis (TBE) in a Patient with X-Linked Agammaglobulinemia; Treatment with TBE Virus IgG Positive Plasma, Clinical Outcome and T Cell Responses.Journal of clinical immunology · 2024Article
- Tick-borne encephalitis infections without CNS involvement: An observational study in Latvia, 2007-2022.PloS one · 2024Observational
- Tick-Borne Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2023Article
- Tick-Borne Encephalitis (TBE): From Tick to Pathology.Journal of clinical medicine · 2023Review
- Recovery and sequelae in 523 adults and children with tick-borne encephalitis in Germany.Infection · 2023Article
- Article
- Transient Expression of Flavivirus Structural Proteins inVaccines · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent decades, the incidence of tick-borne encephalitis (TBE) in Sweden has increased. To calculate the burden of disease over a 17-year period, we analyzed data from the Swedish National Health Data Register for TBE cases diagnosed during 1998-2014. We compared healthcare use and sick leave associated with 2,429 persons with TBE with a referent cohort of 7,287 persons without TBE. Patients with TBE were hospitalized for significantly more days during the first year after disease onset (11.5 vs. 1.1 days), logged more specialist outpatient visits (3.6 vs. 1.2 visits), and logged more sick leave days (66 vs. 10.7 days). These differences generally increased over time. The case-fatality rate for TBE was 1.1%. Our calculated cost of TBE to society provides a baseline for decisions on immunization programs. Analyzing register data, our study adds to clinical studies of smaller cohorts and model-based studies that calculate disease burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.